TY - JOUR
T1 - Prevention of breast cancer in postmenopausal women
T2 - Approaches to estimating and reducing risk
AU - Cummings, Steven R.
AU - Tice, Jeffrey A.
AU - Bauer, Scott
AU - Browner, Warren S.
AU - Cuzick, Jack
AU - Ziv, Elad
AU - Vogel, Victor
AU - Shepherd, John
AU - Vachon, Celine
AU - Smith-Bindman, Rebecca
AU - Kerlikowske, Karla
N1 - Funding Information:
Supported in part by the Daniel and Phyllis Da Costa Fund at the California Pacific Medical Center Foundation (S.R.C.) and a Breast Cancer Surveillance Consortium cooperative agreement CA63740 (K.K.). Dr S. R. Cummings has received research support and consulting fees from Eli Lilly. Dr V. Vogel has received consulting fees and honoraria from Eli Lilly, AstraZeneca, Pfizer, and Novartis. Drs J. Shepherd, K. Kerlikowske, and S. R. Cummings share a patent on a phantom device used for breast densitometry. Dr J. Cuzick is a statistical consultant for AstraZeneca and has served as an advisory board member for Eli Lilly.
PY - 2009/3
Y1 - 2009/3
N2 - Background It is uncertain whether evidence supports routinely estimating a postmenopausal woman's risk of breast cancer and intervening to reduce risk.MethodsWe systematically reviewed prospective studies about models and sex hormone levels to assess breast cancer risk and used meta-analysis with random effects models to summarize the predictive accuracy of breast density. We also reviewed prospective studies of the effects of exercise, weight management, healthy diet, moderate alcohol consumption, and fruit and vegetable intake on breast cancer risk, and used random effects models for a meta-analyses of tamoxifen and raloxifene for primary prevention of breast cancer. All studies reviewed were published before June 2008, and all statistical tests were two-sided.ResultsRisk models that are based on demographic characteristics and medical history had modest discriminatory accuracy for estimating breast cancer risk (c-statistics range = 0.58-0.63). Breast density was strongly associated with breast cancer (relative risk [RR] = 4.03, 95% confidence interval [CI] = 3.10 to 5.26, for Breast Imaging Reporting and Data System category IV vs category I; RR = 4.20, 95% CI = 3.61 to 4.89, for >75% vs <5% of dense area), and adding breast density to models improved discriminatory accuracy (c-statistics range = 0.63-0.66). Estradiol was also associated with breast cancer (RR range = 2.0-2.9, comparing the highest vs lowest quintile of estradiol, P <. 01). Most studies found that exercise, weight reduction, low-fat diet, and reduced alcohol intake were associated with a decreased risk of breast cancer. Tamoxifen and raloxifene reduced the risk of estrogen receptor-positive invasive breast cancer and invasive breast cancer overall.ConclusionsEvidence from this study supports screening for breast cancer risk in all postmenopausal women by use of risk factors and breast density and considering chemoprevention for those found to be at high risk. Several lifestyle changes with the potential to prevent breast cancer should be recommended regardless of risk.
AB - Background It is uncertain whether evidence supports routinely estimating a postmenopausal woman's risk of breast cancer and intervening to reduce risk.MethodsWe systematically reviewed prospective studies about models and sex hormone levels to assess breast cancer risk and used meta-analysis with random effects models to summarize the predictive accuracy of breast density. We also reviewed prospective studies of the effects of exercise, weight management, healthy diet, moderate alcohol consumption, and fruit and vegetable intake on breast cancer risk, and used random effects models for a meta-analyses of tamoxifen and raloxifene for primary prevention of breast cancer. All studies reviewed were published before June 2008, and all statistical tests were two-sided.ResultsRisk models that are based on demographic characteristics and medical history had modest discriminatory accuracy for estimating breast cancer risk (c-statistics range = 0.58-0.63). Breast density was strongly associated with breast cancer (relative risk [RR] = 4.03, 95% confidence interval [CI] = 3.10 to 5.26, for Breast Imaging Reporting and Data System category IV vs category I; RR = 4.20, 95% CI = 3.61 to 4.89, for >75% vs <5% of dense area), and adding breast density to models improved discriminatory accuracy (c-statistics range = 0.63-0.66). Estradiol was also associated with breast cancer (RR range = 2.0-2.9, comparing the highest vs lowest quintile of estradiol, P <. 01). Most studies found that exercise, weight reduction, low-fat diet, and reduced alcohol intake were associated with a decreased risk of breast cancer. Tamoxifen and raloxifene reduced the risk of estrogen receptor-positive invasive breast cancer and invasive breast cancer overall.ConclusionsEvidence from this study supports screening for breast cancer risk in all postmenopausal women by use of risk factors and breast density and considering chemoprevention for those found to be at high risk. Several lifestyle changes with the potential to prevent breast cancer should be recommended regardless of risk.
UR - http://www.scopus.com/inward/record.url?scp=64949188644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=64949188644&partnerID=8YFLogxK
U2 - 10.1093/jnci/djp018
DO - 10.1093/jnci/djp018
M3 - Article
C2 - 19276457
AN - SCOPUS:64949188644
SN - 0027-8874
VL - 101
SP - 384
EP - 398
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 6
ER -